These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11120238)

  • 1. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules.
    Imamura M; Tao HR; Hashino S; Kobayashi S; Mori A; Kobayashi M; Asaka M; Tanaka J
    Transplant Proc; 2000 Nov; 32(7):2448-9. PubMed ID: 11120238
    [No Abstract]   [Full Text] [Related]  

  • 2. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
    Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC
    J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo administration of interleukin-6 in murine allogeneic bone marrow chimeras: early and delayed enhancement of hematopoiesis accompanied with split tolerance but not with graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Tanaka J; Imai K; Han M; Fujii Y; Kobayashi M; Higa T; Kasai M
    Immunobiology; 1994 Jun; 190(4-5):346-67. PubMed ID: 7982720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FK506 inhibits severe graft-versus-host disease without mediating the involvement of perforin and granzyme B.
    Tao HR
    Hokkaido Igaku Zasshi; 1998 May; 73(3):227-37. PubMed ID: 9719949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus.
    Morelli AE; Antonysamy MA; Takayama T; Hackstein H; Chen Z; Qian S; Zurowski NB; Thomson AW
    J Immunol; 2000 Jul; 165(1):226-37. PubMed ID: 10861056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect in cyclosporine A- or FK506-treated mice after syngeneic bone marrow transplantation.
    Hashino S; Imamura M; Tanaka J; Kasai M; Higa T; Asaka M
    Leuk Lymphoma; 1996 Apr; 21(3-4):331-7. PubMed ID: 8726416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by deoxyspergualin of allo-reactive cytotoxic activity in mouse graft-versus-host disease.
    Nemoto K; Hayashi M; Abe F; Takita T; Takeuchi T
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3028-30. PubMed ID: 2650418
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppressive effect of stepronin (TS-5010680) in mice.
    de Giorgi L; Arrigoni-Martelli E; Matossian-Rogers A
    Transplant Proc; 1994 Dec; 26(6):3513-6. PubMed ID: 7998255
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo administration of cytokine in allogeneic bone marrow chimeras.
    Imamura M; Fujimoto H; Hashino S; Fukuhara T; Kobayashi M; Kasai M; Sakurada K; Miyazaki T
    Immunobiology; 1990 Jun; 180(4-5):441-57. PubMed ID: 1697845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin.
    Iwata H; Nagano T; Toyo-oka K; Hirose H; Hamaoka T; Fujiwara H
    Transplant Proc; 1994 Apr; 26(2):851-4. PubMed ID: 7513476
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
    Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
    Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation.
    Mollison KW; Fey TA; Krause RA; Thomas VA; Mehta AP; Luly JR
    Ann N Y Acad Sci; 1993 Jun; 685():55-7. PubMed ID: 7689812
    [No Abstract]   [Full Text] [Related]  

  • 15. Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation.
    Ewing P; Hildebrandt GC; Planke S; Andreesen R; Holler E; Gerbitz A
    Int J Mol Med; 2007 Sep; 20(3):301-8. PubMed ID: 17671733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
    Palathumpat V; Dejbakhsh-Jones S; Strober S
    Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice.
    Fowler DH; Kurasawa K; Smith R; Gress RE
    Prog Clin Biol Res; 1994; 389():533-40. PubMed ID: 7700918
    [No Abstract]   [Full Text] [Related]  

  • 18. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease.
    Bruley-Rosset M; Churaqui E; Annat J; Dutartre P
    Transplant Proc; 1996 Dec; 28(6):3114-6. PubMed ID: 8962208
    [No Abstract]   [Full Text] [Related]  

  • 20. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease.
    Chen Y; Schlegel PG; Tran N; Thompson D; Zehnder JL; Chao NJ
    Blood; 1997 Feb; 89(4):1452-9. PubMed ID: 9028970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.